

## Special Issue

# New Antivirals against Coronaviruses

### Message from the Guest Editor

The aim of this Special Issue is to gather articles (research articles, short communications, and reviews) to visualize and contribute to broadcast the recent advances in the discovery and development of new antiviral candidates as well as innovative therapies for coronaviruses, including nanotechnologies, monoclonal antibodies, genome editing, and other alternatives directed to inhibit viral replication.

---

### Guest Editor

Dr. Nadine Alvarez

Center for Discovery and Innovation, Hackensack Meridian Health,  
Nutley, NJ, USA

---

### Deadline for manuscript submissions

1 September 2025



## COVID

---

an Open Access Journal  
by MDPI

---

Impact Factor 1.0  
CiteScore 2.3



[mdpi.com/si/213704](https://mdpi.com/si/213704)

*COVID*

Editorial Office

MDPI, Grosspeteranlage 5

4052 Basel, Switzerland

Tel: +41 61 683 77 34

[covid@mdpi.com](mailto:covid@mdpi.com)

[mdpi.com/journal/](https://mdpi.com/journal/)

[covid](https://mdpi.com/journal/covid)





# COVID

---

an Open Access Journal  
by MDPI

---

Impact Factor 1.0  
CiteScore 2.3



[mdpi.com/journal/  
covid](https://mdpi.com/journal/covid)



## About the Journal

### Message from the Editor-in-Chief

---

#### Editor-in-Chief

Prof. Dr. Giuseppe Novelli

Department of Biomedicine & Prevention, Genetics Section, University  
of Rome Tor Vergata, 00133 Rome, Italy

---

#### Author Benefits

##### Open Access:

free for readers, with article processing charges (APC) paid  
by authors or their institutions.

##### High Visibility:

indexed within ESCI (Web of Science), Scopus, CAPus /  
SciFinder, and other databases.

##### Journal Rank:

CiteScore - Q2 (Immunology and Microbiology  
(miscellaneous))